Liu Xiao-Qin, Wang Xiao-Yu, Shen Hui-Ming, Pang Wen-Yuan, Zhong Ming-Kang, Ma Chun-Lai
Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Nanjing, China.
Front Pharmacol. 2022 May 12;13:858139. doi: 10.3389/fphar.2022.858139. eCollection 2022.
Pharmacotherapy is one of the main treatments for patients with young-onset Parkinson's disease (YOPD). Although numerous studies on the treatment of YOPD have been published, the real-world prescription patterns of these populations remain unclear in China. A national comprehensive evaluation was performed to reveal the pharmacological treatment patterns in Chinese patients with Parkinson's disease from 1 January 2014 to 31 December 2019, with patients aged 21-50 years classified as having YOPD for the subgroup analysis. Information on patients and drugs was extracted to analyse the demographic characteristics, prescription patterns, and levodopa equivalent daily dose (LED) during disease progression. A total of 1,134 patients with YOPD were included, and the majority were aged 41-50 years. Prescription of L-DOPA/benserazide and pramipexole accounted for more than 30 and 20%, respectively, in each year from 2014 to 2019. There was no difference in prescription patterns in terms of age, sex and geographical areas. Half of the patients with YOPD were on monotherapy, but the proportion decreased from 2016. Correspondingly, the proportion of patients receiving polytherapy increased, especially those who were prescribed more than two anti-Parkinson's disease drugs. During the disease course, LED showed high variability, which increased over time. L-DOPA/benserazide and pramipexole were the most frequently prescribed anti-PD drugs for patients with YOPD in China. There was a slight trend in the transition from monotherapy to polytherapy. LED increased with disease duration. Thus, we provided an overview of the prescription patterns for patients with YOPD in China.
药物治疗是青年型帕金森病（YOPD）患者的主要治疗方法之一。尽管已经发表了许多关于YOPD治疗的研究，但在中国这些人群的真实世界处方模式仍不清楚。进行了一项全国性综合评估，以揭示2014年1月1日至2019年12月31日期间中国帕金森病患者的药物治疗模式，将年龄在21 - 50岁的患者归类为YOPD进行亚组分析。提取患者和药物信息，以分析疾病进展过程中的人口统计学特征、处方模式和左旋多巴等效日剂量（LED）。共纳入1134例YOPD患者，大多数年龄在41 - 50岁。在2014年至2019年的每年中，左旋多巴/苄丝肼和普拉克索的处方分别占比超过30%和20%。在年龄、性别和地理区域方面，处方模式没有差异。一半的YOPD患者接受单药治疗，但该比例自2016年起下降。相应地，接受联合治疗的患者比例增加，尤其是那些被处方两种以上抗帕金森病药物的患者。在疾病过程中，LED显示出高度变异性，且随时间增加。左旋多巴/苄丝肼和普拉克索是中国YOPD患者最常处方的抗帕金森病药物。从单药治疗到联合治疗有轻微趋势。LED随疾病持续时间增加。因此，可以了解中国YOPD患者的处方模式概况。
